Completed PHASE2 INTERVENTIONAL 2-arm NCT00490646

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer

Sponsor: R-Pharm

Conditions Metastatic Breast Cancer

Interventions docetaxel ixabepilone trastuzumab

Updated 7 times since 2017 Last updated: Feb 9, 2016 Started: Feb 29, 2008 Primary completion: Jun 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00490646, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by R-Pharm, it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Athens, Greece , Bologna, Italy , Brescia, Italy , Caen, France , Grenoble, France , Izmir, Turkey (Türkiye) , Madrid, Spain , Modena, Italy , Napoli, Italy and 5 more locations